FDA Approves CELLCEPT — Genentech, Inc.

The FDA has re-approved CELLCEPT (mycophenolate mofetil) following the transfer of the NDA to global markets, ensuring Genentech maintains continued exclusivity and market protection in the U.S. despite the recent marketing exclusivity changes for the generic.